clinical mechanism map derived

{
  "input": {
    "type": "http",
    "method": "GET",
    "queryParams": {
      "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
      "condition": "Disease — e.g. \"Treatment-Resistant Depression\" | \"ALS\" | \"Lupus\" | \"Multiple Sclerosis\" | \"Prostate Cancer\"",
      "mechanism": "Optional — specific mechanism to focus on, e.g. \"BTK inhibitor\" | \"IL-17\" | \"CAR-T\""
    }
  },
  "output": {
    "type": "json",
    "example": {
      "query_summary": {
        "condition": "Multiple Sclerosis",
        "mechanism": null
      },
      "key_publications": [
        {
          "year": "2024",
          "title": "BTK inhibitors in progressive MS — mechanisms and clinical data",
          "journal": "Nature Reviews Neurology"
        }
      ],
      "mechanism_landscape": {
        "white_spaces": [
          "Progressive MS neuroprotection",
          "Remyelination",
          "CNS innate immunity",
          "Biomarker-stratified precision approaches"
        ],
        "crowded_spaces": [
          "Anti-CD20 (3 approved, 2 in pipeline)",
          "S1P modulators (4 approved)",
          "Natalizumab analogues"
        ],
        "approved_mechanisms": [
          {
            "moa": "Anti-CD20 (B cell depletion)",
            "drugs": [
              "Ocrelizumab",
              "Ofatumumab",
              "Ublituximab"
            ],
            "notes": "Dominant mechanism for RRMS — 3 approved"
          },
          {
            "moa": "S1P receptor modulator",
            "drugs": [
              "Fingolimod",
              "Siponimod",
              "Ozanimod",
              "Ponesimod"
            ],
            "notes": "Oral DMT — 4 approved; class mature"
          },
          {
            "moa": "BTK inhibitor",
            "drugs": [],
            "notes": "No approvals yet — 6 agents in Phase 2/3"
          }
        ],
        "pipeline_mechanisms": [
          {
            "moa": "BTK inhibition (CNS-penetrant)",
            "phase": "PHASE3",
            "agents": [
              "Fenebrutinib (Roche)",
              "Tolebrutinib (Sanofi)",
              "Evobrutinib (Merck)"
            ],
            "crowding": "Moderate (3 Phase 3)",
            "differentiation": "Targets microglial activation — may address progressive MS unlike existing agents"
          },
          {
            "moa": "Remyelination (opioid receptor modulation)",
            "phase": "PHASE2",
            "agents": [
              "Opicinumab (Biogen)"
            ],
            "crowding": "Low",
            "differentiation": "Novel — no approved remyelinating agents"
          }
        ]
      },
      "drug_discovery_implications": "BTK inhibition is the most clinically advanced novel mechanism. CNS penetration and microglial targeting differentiate from older agents. Progressive MS remains the largest unmet need.",
      "first_in_class_opportunities": [
        "BTK inhibitors for progression (if Phase 3 data positive)",
        "Remyelinating agents (no approved class)"
      ]
    }
  }
}